View Article

Abstract

Transungual drug delivery refers to the administration of therapeutic agents through the nail plate, providing a direct and effective route for treating localized nail and nail bed disorders. This review explores the anatomy of the nail, the factors influencing drug diffusion through the nail, and the challenges and strategies in overcoming these barriers. The nail’s unique structure, including its multiple layers and permeability properties, plays a crucial role in the effectiveness of transungual delivery systems. Additionally, the review highlights common nail diseases, particularly onychomycosis—a fungal infection that significantly impacts both health and quality of nail. This review article explores the various types of onychomycosis, its underlying pathophysiology, and current pharmacological treatments, with a particular focus on antifungal agents. Additionally, transungual delivery methods, including topical therapies and novel formulation approaches, are critically examined for their potential to enhance therapeutic outcomes. Finally, we explore advancements in topical therapies, including formulations and technologies designed to enhance drug penetration and efficacy, offering insights into promising future directions in transungual drug delivery for treating nail diseases, particularly onychomycosis.

Keywords

Transungual drug delivery; Onychomycosis; Nail disorders; Topical therapies.

Introduction

Transungual drug delivery refers to a system designed for transporting drugs through the nail to achieve targeted treatment for nail diseases. The term "transungual" is derived from "trans," meaning "through," and "unguis," meaning “nail” [1]. The hardness and low permeability of the nail have traditionally made it a difficult path for drug delivery. Improving topical drug delivery for nail conditions like onychomycosis and nail psoriasis could reduce the reliance on systemic medications and their associated side effects. This strategy may also shorten treatment time and decrease the chances of recurrence [2]. Compared to oral versions like pills, ungual treatment has several advantages over oral or systemic medication delivery, including easier preparation. Additionally, it gets rid of systemic adverse effects and drug interactions. Local side effects, such as periungual erythema (redness around the nail fold), are uncommon but usually go away within minutes, as the body adapts to the drug. Because ungual treatment uses a topical preparation that is simple to remove if needed, it has little systemic absorption. It helps prevent possible drug interactions, enhances patient adherence, and is appropriate for people who are unable to take systemic medications, such as the elderly or those on many medications. Despite its benefits, ungual therapy faces challenges, including the nail plate’s composition, which restricts drug penetration. This means only a small fraction of the topical medication can penetrate, preventing the attainment of the desired therapeutic concentration [3].

Anatomy of a Nail

The human nail acts as an essential organ, like the claws of other mammals. It serves multiple functions, including protecting the tips of the fingers and toes from injury, enhancing tactile sensitivity, and assisting in object manipulation. Nails vary in size, shape, and texture, creating a thicker barrier that increases the distance drugs must travel for diffusion. The nail's physicochemical properties suggest it behaves like a hydrophilic gel membrane, while the stable disulfide bonds responsible for its hardness are thought to restrict drug penetration [4]. The nail plate is mainly composed of keratin molecules, which are linked by numerous disulfide bonds, and contains very little lipid content [5].

The human nail consists of the following parts (as shown in Fig 1):

Figure 1. Parts of a Nail

Nail Plate

The firm, keratinized structure on the surface of the fingers and toes is called the nail plate. It acts as the primary barrier to medication entry and is composed of densely packed keratin layers. Because of its thick nature, it is challenging to absorb drugs via the nail plate.

Nail Bed

Beneath the nail plate is the nail bed, a soft tissue rich in blood vessels that provide nutrients to the nail. For effective treatment, medications need to reach the nail bed in order to treat infections or conditions beneath or within the nail plate.

Perionychium

The perionychium refers to the skin around the edges of the nail, providing added protection. However, it does not play a direct role in drug absorption. The unique structure and function of each layer of the nail influence how effectively medications can be delivered for the treatment of nail disorders [6].

Hyponychium

The hyponychium is the skin located beneath the free edge of the nail, serving as a protective barrier to prevent pathogens and foreign substances from entering beneath the nail. This layer can also influence the application and absorption of topical medications.

Eponychium

The eponychium, or cuticle, is found at the base of the nail plate. It serves as a protective barrier against infections and environmental elements. Like the hyponychium, it can affect the effectiveness of topical treatments applied to the nail area.

Nail Matrix

The nail matrix, situated beneath the cuticle at the base of the nail, is where nail growth originates. It produces new keratin cells, which allow the nail to grow. Targeting the matrix is vital when treating conditions that impact nail growth, like psoriasis or fungal infections.

Nail Root

The germinal matrix, also known as the nail root (radix unguis), is located several millimetres into the finger, beneath the skin at the lower edge behind the fingernail. Together with the nail bed, the nail root contributes to the nail's volume. This area lacks melanocytes, the cells responsible for producing melanin. The lunula, a white, crescent-shaped structure, is believed to represent the boundary of the germinal matrix [7-8].

Figure 2. Illustration showing Human Nail Anatomy

Factors Affecting Drug Diffusion Through Nail

The effectiveness of nail drug treatments depends on factors like molecule size, solubility, and formulation. Larger molecules face resistance from the nail's keratin structure, limiting their ability to penetrate, while smaller molecules can diffuse more easily. Hydrophilic drugs struggle to pass through the nail’s hydrophobic surface, whereas lipophilic drugs penetrate more readily. The pH of the formulation affects drug ionization, with neutral, uncharged molecules generally penetrating better than charged ones. Solvent choice is also important; hydrophilic solvents hydrate the nail, expanding keratin fibers to improve absorption. Application techniques, such as ensuring thorough contact, and longer treatment durations can increase drug penetration. Nail thickness can act as a barrier, and the condition of the nail, whether damaged or infected, further impacts drug absorption and overall effectiveness.

Types of Nail Diseases

Nail diseases encompass a wide range of conditions affecting the structure, appearance, and health of nails. These include infections like fungal onychomycosis, inflammatory disorders such as psoriasis, and deformities like ingrown nails. Nail diseases can arise from infections, trauma, systemic diseases, or nutritional deficiencies, often impacting quality of life. Understanding their types, causes, and symptoms is essential for accurate diagnosis and effective treatment strategies. Table 1 gives a summary on various nail diseases, their causes, and symptoms.

Table 1. Detailed Description of Nail Diseases, their Causes and Symptoms

Condition

Description

Symptoms

Causes/Risk Factors

References

Paronychia

Infection of the nail fold caused by bacteria, fungi, or viruses.

Pain, redness, and swelling around the nail folds.

Prolonged exposure to water; highly contagious.

 

[9]

Pseudomonas Infection

natural nail plate and the nail bed or beneath artificial nails.

Nail darkening, discoloration, detachment.

Thrives in damp environments.

[10]

Fungal Infection (Onychomycosis)

tears in the nail folds.

Onycholysis, discoloration, texture changes.

Tears in proximal or lateral nail folds, involving other microorganisms.

[11]

Tinea Unguis

Ringworm of the nails, this infection results in nail thickening.

Nail deformity, leading to eventual loss of the nail plate.

Fungal infection.

[12]

Onychatrophia

Atrophy or degeneration of the nail plate.

Loss of shine, smaller nails, and potential shedding.

Injury or disease.

[13]

Onychogryposis

Claw-shaped nails with thickened plates,

Thickened, curved nails that pinch the nail bed.

Trauma.

[14]

Onychorrhexis

Brittle nails that crack or peel.

Vertical splits, peeling, and ridges on the nail.

Genetics and frequent use of strong solvents.

[15]

Leuconychia

White lines or spots on the nail plate.

Visible white spots or streaks on the nail.

Trauma and genetic factors.

[16]

Beau's Lines

Horizontal lines of darkened cells and indentations.

Linear depressions on the nails and darkened nail color.

Trauma, illness, malnutrition, and chemotherapy.

[17]

Koilonychia

Concave nails, often associated with iron deficiency.

Thin, concave nails with elevated ridges.

Iron deficiency anemia.

[18]

Hematoma

Blood trapped beneath the nail plate due to trauma.

Painful discoloration with potential nail separation.

Trauma from various sources, such as tight shoes or sports injuries.

[19]

Onychomycosis

Onychomycosis is a fungal infection affecting nails, resulting in changes to their appearance, texture, and structure as shown in Figure.3. While it predominantly impacts toenails, fingernails can also be affected. The infection is caused by various fungi, including dermatophytes, yeasts, and molds, with T. rubrum being the most common culprit. Fingernail infections are often associated with Candida species, particularly C.albicans, and frequently co-occur with paronychia. This chronic condition can affect both toenails and fingernails, accounting for 50% of nail infections and 30% of superficial fungal skin infections. It is a globally occurring disease with diverse presentations and prevalence rates influenced by geographic, climatic, and demographic factors [20].

Epidemiology

Onychomycosis accounts for half of all nail diseases and affects about 5.5% globally, with earlier studies showing 2–8%. Prevalence is highest in Europe (23%) and East Asia (20%), with North America reporting up to 14%. Rates in Greece range from 15.7% in the south to 20% in the north. Gender disparities are notable; toenail infections are more common in men (81.49%) due to nail trauma and sports injuries, while fingernail infections are more frequent in women (39.74%), linked to prolonged moisture exposure from housework, manicures, and nail care, which may damage the protective eponychium.

Figure 3. Clinical image of Onychomycosis

Symptoms

The condition typically presents with nail discoloration, thickening, brittleness, and distortion. In severe cases, the nail may separate from the nail bed, making it difficult to trim and more vulnerable to damage.

Causes and Risk Factors

Onychomycosis is caused by fungi that thrive in warm, moist environments, such as public showers or poorly ventilated footwear. Risk factors include:

  • Advanced age
  • Diabetes
  • Immunosuppression
  • Foot or nail injuries
  • Poor hygiene

Etiology

Dermatophytes are the leading pathogens, responsible for approximately 90% of toenail infections and 50% of fingernail cases. T.rubrum is the most common pathogen, followed by T. mentagrophytes. Dermatophyte-related nail infections are collectively referred to as tinea unguium. Non-dermatophyte molds (NDMs) also contribute to onychomycosis, primarily affecting toenails. NDMs account for 1.5–6% of cases and include consistently pathogenic fungi (S. dimidiatum, S. hyalinum) and opportunistic fungi (S. brevicaulis, A. sydowii, O. canadensis). Yeasts, particularly Candida albicans, are increasingly recognized as significant pathogens in fingernail infections. C. albicans is responsible for about 70% of cases, with other species such as C. parapsilosis, C. tropicalis, and C. krusei also implicated. Candida infections are more prevalent among individuals with weakened immune systems due to vascular diseases, diabetes, immunosuppression, aging or the use of broad-spectrum antibiotics.Certain conditions, including agammaglobulinemia, DiGeorge syndrome, and thymus dysplasia, further increase susceptible.

Types of Onychomycosis

There are six primary forms of onychomycosis, each of which affects the nails differently: white superficial, distal and lateral subungual, candidal, proximal subungual, total dystophic and endonyx. Table.2 gives a summary on the above-mentioned types of onychomycosis, their common causes, affected areas and their clinical features [21].

Table 2. Types of Onychomycosis, causative organism, areas affected and clinical features

Type of Onychomycosis

Common Cause

Affected area/Clinical Features

Drugs

Distal Subungual Onychomycosis

T. rubrum (most common), other dermatophytes

Nail plate, distal end -Thickened, discolored (yellow/brown), crumbling, onycholysis

Terbinafine- Oral tablet, Topical cream/gel

White Superficial Onychomycosis

T. mentagrophytes, Candida species

Surface of nail plate -White, chalky spots, rough nail surface

Ciclopirox- Topical nail lacquer, Topical cream/gels

Proximal Subungual Onychomycosis

T. rubrumC. albicans

Nail matrix (near cuticle)-Nail lifting, discoloration at base, thickening

Itraconazole- Oral capsule, Oral solution

Candidal Onychomycosis

C.albicans,

C. parapsilosis

Typically fingernails -Swelling, pain, discoloration, brittle nails

Fluconazole- Oral tablet, Oral suspension

Endonyx Onychomycosis

T. rubrum, dermatophytes

Nail plate (under surface)-Subtle changes, nail opacity, no surface damage

Griseofulvin- Oral tablet, Oral suspension

Total Dystrophic Onychomycosis

Dermatophytes, yeasts, molds

Entire nail -Complete destruction, thickening, deformity

Efinaconazole-Topical solution

Methods of Transungual Drug Delivery

The following are the various methods of transungual drug delivery

  1. Surgical Delivery
  2. Systemic Drug Delivery
  3. Topical Drug Delivery
  1. Passive Drug Delivery
  2. Device Based Drug Delivery
  1. Biophysical Therapy
  1. Laser Therapy
  2. Carbondioxide Lasers
  3. Photodynamic Therapy
  4. Etching

Surgical Delivery

In both cases of total and partial nail avulsion, the affected nail plate is surgically removed, either completely or partially, while under local anesthesia. Salicylic acid and urea are examples of keratolytic agents that soften the nail plate in preparation for avulsion. For nonsurgical avulsion, urea or urea and salicylic acid in combination have been utilized [22].

Systemic Drug Delivery

A relatively small amount of drug may reach the site of action when taken orally or parenterally. While this approach is better in an emergency, it is not the best option for long-term nail treatment [23].

Topical Drug Delivery

  1. Passive Topical Drug Delivery

In cases of lateral and distal subungual onychomycosis, lacquer is the recommended treatment. Infection of the nail matrix, however, renders it ineffective. Nail lacquer is recommended to be applied once or twice a week for a duration of five to ten months. When the nail matrix treatment is not used, the complete and mycological cure rates for this lacquer have been reported to range from 38–54% and 60–76%, respectively.Burning, irritation, itching, redness, and discomfort are the most frequent negative side effects [24].

  1. Device Based Topical Drug Delivery
  1. IontophorosisIt is the process of applying an electric field (electromotive force) to transfer a substance across a membrane. Iontophoresis may improve drug diffusion through a nail's hydrated keratin.
  2. Ultrasound technique: The canine hoof model has been used to test the effectiveness of this technique in delivering medications across the nails. The canine hoof membrane was marked with blue dye and subjected to three energy levels for 120 seconds at 1.5 W/cm2 power, with blue dye as a marker. Drug absorption increases by 1–5 times when compared to alternative methods [25].
  3. UV photodynamic therapy: In treating conditions relating to the skin, photodynamic therapies have demonstrated remarkable results.When alpha linolenic acid (10 mM) was added to dermatophytes like Candida albicans and Trichophyton interdigitale, and the organisms were then exposed to light, their viability reduced.

Biophysical Therapy

  1. Laser Therapy

The target tissues can be directly heated by lasers with wavelengths in the near-infrared (780–3000 nm) range. A microsurgical laser device that creates nail holes and applies topical antifungals to treat onychomycosis has been patented. There is a lot of work left to characterize this invention named ‘onycholaser’.

  1. Carbondioxide Laser

Topical antifungal medication and fractional carbon dioxide laser therapy should be used in combination. A topical application of antifungal cream after nail plates were perforated with ablative carbon dioxide improved the look. [26].

  1. Photodynamic Therapy

The fundamental idea behind this treatment is the way photosensitizers and visible spectrum light interacts. The product of the reaction between photosensitizing chemicals and visible spectrum light is singlet oxygen. Fungal cells can die because of a reaction between singlet oxygen and their biological components [27].

  1. Etching

Tiny micropores are created on the nail plate's surface during the etching process. By creating microporosities on the nail surfaces, certain surface-modifying substances like tartaric acid and phosphoric acid or tools like path former reduce the contact angle and improve the surface on which the medication can attach. An FDA-approved tool called a path forming helps drain subungual hematomas by making tiny pinholes in the nails without damaging the nail bed. The gadget does not require anesthetic because it uses the electrical resistance of the nail as feedback. A 400-μm tissue cutter is used to drill the nail plate, and once it has entered the nail plate, it is retracted.

Topical Therapeutic Approaches

Therapeutic approaches for transungual delivery focus on the development of treatments that effectively penetrate the nail plate to target infections or conditions beneath the nail. This method aims to overcome the natural barrier of the nail, enhancing the absorption of antifungal agents or other medications. Advances in formulations like nail lacquers, gels, and nanoparticles are improving the efficacy of transungual drug delivery for conditions like onychomycosis. The topical therapeutic approaches are shown in the following Figure 4:

Figure 4. Topical Therapeutic Approaches

Gels

Gels or hydrogels are created from natural or synthetic hydrophilic polymers that dissolve in a solvent, forming a three-dimensional structure [28]. Due to their ability to retain significant amounts of water and hydrate the nail plate, thereby improving drug absorption, they are commonly used in the treatment of nail disorders [29]. Gels are difficult to apply because of their viscosity, and they tend to wear off the nail surface during daily activities. These are some disadvantages of using gels to treat nail diseases. These issues have prompted the creation of in situ gelling solutions, which, when certain parameters (temperature, pH, and ionic strength) are changed, such as after being applied to the nail, transform from a liquid state into a gel (Sol–Gel Transition) [30]. One well-known example of a material that changes because of temperature changes is polxamers. Additionally, gels can be used in conjunction with iontophoresis to transfer charged drug molecules across the nail plate because they are hydrophilic [31].

Nail Lacquer

In general, nail illnesses cannot be effectively treated using conventional pharmaceutical topical systems such gels, lotions, creams, suspensions, or solutions because they cannot remain at the application site long enough to allow drug penetration. In these situations, nail lacquers or paints are usually applied to improve the efficacy of antifungal drugs [32]. The primary ingredients of nail lacquers are volatile solvents and film-forming polymers, which are either water-soluble or insoluble resins. These substances dry rapidly, leaving a smooth layer on the nail plate that serves as a drug release depot [33]. Ciclopirox and Amorolfine, antifungal medications, are sold as nail lacquers. They are recommended to be administered following nail abrasion. The FDA-approved hydro-lacquer Penlac R includes 8% ciclopirox, whereas the water-insoluble nail lacquer Loceryl R has 5% amorolfine [34]. The addition of various polymers to nail lacquers, such as dual acrylate–silicone hybrid copolymer and hydroxyl propyl chitosan, increased ciclopirox and ketoconazole penetration, respectively [35].

Patches and Films

Since nail patches offer a delayed release of medication, they have become a better option than nail lacquers for reducing treatment durations and enhancing patient compliance. Typically, it consists of a release liner, a drug-impermeable backing membrane, and a pressure-sensitive adhesive matrix that serves as a medication reservoir. For two days, ALA patches are able to maintain the drug release [36]. Transungual films, which are made using hot melt extrusion or film casting techniques, offer prolonged drug release. Mididoddi et al. used hot melt extrusion to create a film of the ketoconazole medication based on hydroxy propyl cellulose [37].

Nano Emulsions

An isotropic biphasic mixture of two phases—oil and water—in which one phase is distributed as nanoparticles in the other is called a nano-emulsion. An interfacial layer of surfactants is used to stabilize the system [38]. The appearance of these nano-emulsion systems is translucent or transparent. Nano-emulsions have a higher thermodynamic stability than other lipid carriers. When compared to simple micelle solutions, nano-emulsions show a higher solubilization capacity [39-40].

Nano-Emulgel Drug Delivery System

By combining the nano-emulsion with a hydrogel matrix, nano-emulgel is created, which lessens the emulsion's thermodynamic instability. Because of the greater consistency of the external medium, the non-aqueous phase's mobility is reduced, which results in improved thermodynamic stability. The formulation can release the drug over time due to its improved retention time and thermodynamic stability, which makes nano-emulgel a controlled release dosage form for topical administration that is advantageous for medications with a short half-life [41-42]. These systems also benefit from pharmacokinetic characteristics including improved absorption and fewer adverse effects. The hydrogel matrix, uniformity, and consistency have contributed to the increased interest in nano-emulgels [43].

Drugs Used for Treatment of Different types of Onychomycosis

The kind and intensity of the fungal infection determine how onychomycosis is treated. Antifungal medications, both topical and systemic, are commonly used to target the underlying fungal organisms. Drugs like terbinafine, itraconazole, and fluconazole are often prescribed to treat different forms of onychomycosis, aiming to eliminate the infection and restore healthy nail growth [44]. The drugs used for treatment of Onychomycosis are as shown in Table 3.

Table 3. Medications used in the treatment

Drug

Nanosystems

Key Outcomes

References

Amphotericin B

Nail lacquer

  • The Ampotercin B- loaded nail lacquer demonstrated effective antifungal activity,desirable physiochemical properties (water resistance, adhesion), and stable formulation,with 90% of amphotericin B released in 3 hours and 47.76% permeating the nail matrix in 24 hours
  • The formulation showed potential for treating candida induced onychomycosis and could be further explored for use against other fungi like Trichophyton rubrum.

(45)

Itraconazole

Microemulsion-based gel as colloidal carrier for itraconazole

  • The microemulsion formulation was optimized using D-optimal design, achieving a globule size of 48.2 nm and drug loading of 12.13 mg/ml.
  • The drug-loaded gel showed better retention in bovine hoof and human skin, with enhanced antifungal activity compared to the market formulation, indicating potential for faster onychomycosis treatment.

(46)

Efinaconazole

Microemulsion formulation (using Capmul® MCM

(Glyceryl Caprylate/Caprate) as oil, Labrasol® (caprylocaproyl polyoxyl-8 glycerides) as a surfactant, and

Transcutol® P (diethylene glycol monoethyl ether) as a co surfactant)

  • A microemulsion formulation for efinaconazole was optimized for enhanced transungual delivery, showing small globules (<100 nm) and stable gel form with 1% Carbopol® 934 P.
  • The formulation demonstrated improved ex vivo permeation, better antifungal activity against Trichophyton rubrum, T. mentagrophytes, and Candida albicans, and showed no cytotoxicity, suggesting its potential for onychomycosis treatment.

(47)

Ketoconazole

Nanoemugel

  • In vitro release and ex vivo permeation study of the optimized nanoemulgel (NEG1) showed better efficacy, as compared to drug suspension. The optimized nanoemulgel (NEG1) showed enhanced in vitro antifungal activity on T. rubrum and C. albicans as compared to drug solution in DMSO and thus could be a promising formulation to reduce the symptoms of and cure onychomycosis faster than the conventional therapies.

(48)

Naftifine Hydrochloride

Nail lacquers

  • The study optimized nail lacquer formulation for transungual drug delivery using Eudragit RlL100 and RS100, confirmed through testing of drying time,water resistance, and in vitro release. The optimization process successfully defined the composition and quality of naftifine hydrochloride lacquers, ensuring their suitability for further development.

(49)

Terbinafine Hydrochloride

Nail lacquer

  • The study showed that a combination of hydrophobic and hydrophilic polymers significantly enhanced drug permeability (39.00 μg/cm²/h) and retention(47.12%) in the nail plate, outperforming commercially available creams. SEM analysis revealed that penetration enhancers improved the structural integrity of the hoof, facilitating better drug permeation, making drug loaded nail lacquers a promising treatment for onychomycosis.

(50)

AR-12

Topical formulation using dexpanthenol and PEG400 as penetration enhancers

  • AR-12 a promising drug for onychomycosis, showed enhanced ungual and transungual delivery using dexpanthenol and PEG 400 as penetration enhancers, with in vitro studies delivering ~3.56 μg of AR-12 across the nail paint. These enhancers can be used in future topical formulation to deliver sufficient AR-12 for effective treatment

(51)

CONCLUSION

In conclusion, transungual drug delivery offers a promising solution for treating nail diseases, particularly onychomycosis, by overcoming the challenges posed by the nail's low permeability. Advances in formulation technologies, such as nano-based systems, lipid carriers, and iontophoresis, have significantly improved drug penetration, making it possible to achieve higher local drug concentrations with fewer systemic side effects. These innovations hold great potential for more effective, targeted therapies for nail infections. Future progress in optimizing delivery methods and personalized treatments will further enhance the efficacy of transungual therapies, ultimately improving patient outcomes and quality of life.

AUTHOR CONTRIBUTIONS:

Conceptualization, M.N. and S.K.; methodology, N.K., B.P.; writing—original draft preparation, M.N., S.K., N.K., B.P.; writing—review and editing, M.N., R.A.; All authors have read and agreed to the published version of the manuscript.

CONFLICT OF INTEREST:

The authors declare no conflict of interest.

REFERENCES

  1. Hussan D, Choudhary SR, Sharma D, Bhandari V, Singh M. Transungual drug delivery: a novel approach with unique features. Indo Am J Pharm Res. 2013;3(6):4460-9. doi:10.1155/2016/1387936.
  2. Firoz S, Sirisha MN, Rajalakshmi R. Transungual drug delivery system: a review. Int J Innov Drug Disc. 2011;1:9-14.
  3. Kumar PT, Narayana RP. Transungual drug delivery: a promising route to treat nail disorders. Int J Pharm Res. 2013;2:22-3.
  4. Verma S, Verma S, Singh R, Ashima A. Transungual drug delivery: a pivotal remedy in onychomycosis. 2016:370-81.
  5. Nikam VK, Kotade KB. Transungual drug delivery system: a review. Pharmacologyonline. 2011;1(1):126-39.
  6. Sahoo CK, Mohanty D. Transungual drug delivery system: a review. Asian J Pharm Res. 2015;5(1):37-44.
  7. Yadav V, Srivastava V, Dwivedi KP, Singh R, Yadav A, Verma NK. Disease of nails (fungal infection), diagnosis, treatment (nail lacquer): a review. World J Pharm Pharm Sci. 2013;11(10):663-94. doi:10.20959/wjpps202210-23344.
  8. Malvade PV, Chavan SR, Bhagat DB, Ghorpade KR. Transungual: the novel drug delivery system. World J Pharm Life Sci. 2020;6(6):265-74.
  9. Basini NP, Dey BK. Nail drug delivery system: a review. J Adv Pharm Educ Res. 2012;2(3):101-9.
  10. Kiran SR, Chandra Shekar B. Ungual drug delivery system of ketoconazole nail lacquer. Int J Appl Pharm. 2010;2(4):17-9.
  11.  Patel RP, Patel NA. Drug delivery across human nail. Int J Curr Pharm Res. 2009;1(1):17.
  12. Badola A, Satish, Baluni S. A review: transungual drug delivery. Asian J Pharm Sci Technol. 2015;5(4):227-33.
  13.  Rajendra VB, Baro A. Transungual drug delivery: an overview. J Appl Pharm Sci. 2012;2(1):203-9.
  14. Mathew F, Bindumol KC. Understanding our natural nail – antifungal agents. Int J Pharm Pharm Sci. 2014;6(2):918-22.
  15. Patil PS, Badgujar SV. Nailing the nail trouble by transungual drug delivery. Eur J Pharm Med Res. 2015;2(2):551-71.
  16. Mathew F, Alias M. Preungual delivery system – a review. Int J Instit Pharm Life Sci. 2014;4(3):44-63.
  17. Lebo DB, Palliyil B. A novel transungual formulation for delivery of ciclopirox olamine. Int J Pharm Med. 2014;3(3):152-64.
  18. Khan AD, Giri A. Transungual drug delivery: a newer approach. World J Pharm Pharm Sci. 2014;3(3):781-94.
  19. Turner R, Weaver S. A novel vehicle for enhanced drug delivery across the human nail. Int J Pharm Compounding. 2016;20(1):71-80.
  20. Gregoriou S, Mpali N, Vrioni G, Hatzidimitriou E, Chryssou S, Rigopoulos D. Epidemiology of onychomycosis in an academic nail unit in South Greece during a three-year period. Skin Appendage Disord. 2019;6(2):102-7. doi:10.1159/000504812.
  21. Singal A, Khanna D. Onychomycosis: diagnosis and management. Indian J Dermatol Venereol Leprol. 2011;77(6):659. doi:10.4103/0378-6323.86475.
  22. Karuna B, Sreekanth N. Nail drug delivery system: a novel approach for drug delivery system. Int J Pharm Res Bio-Sci. 2013;2(2):313-31.
  23. Bhuptani RS, Deshpande KM. Transungual permeation: current insights. Drug Deliv Transl Res. 2015;1(1):1-14. doi:10.1007/s13346-015-0259-6.
  24. Kushwaha A, Murthy NS. Iontophoresis for drug delivery into the nail apparatus: exploring hyponychium as the site of delivery. Drug Dev Ind Pharm. 2016;1(1):1-17. doi:10.3109/03639045.2016.1165690.
  25. Kushwaha A, Murthy RN. Emerging therapies for the treatment of ungual onychomycosis. Drug Dev Ind Pharm. 2015;1(1):1-7. doi:10.3109/03639045.2015.1033426.
  26. Gupta AK, Simpson FC. Routes of drug delivery into the nail apparatus: implications for the efficacy of topical nail solutions in onychomycosis. J Dermatolog Treat. 2015;1(1):1-3. doi:10.3109/09546634.2015.1034081.
  27. Thatai P, Tiwary AK. Progressive development in experimental models of transungual drug delivery of anti-fungal agents. Int J Cosmet Sci. 2016;38:1-12. doi:10.1111/ics.12230.
  28. Calo E, Khutoryanskiy VV. Biomedical applications of hydrogels: a review of patents and commercial products. Eur Polym J. 2015;65:252-67. doi:10.1016/j.eurpolymj.2014.11.024.
  29. Dhamoon RK, Popli H, Gupta M. Novel drug delivery strategies for the treatment of onychomycosis. Pharm Nanotechnol. 2019;7(1):24-38. doi:10.2174/2211738507666190228104031.
  30. Giri Y, Behera A, Mohanty B, Pattnaik G, Habibullah S. Transungual drug delivery system for the topical treatment of onychomycosis: a review. Drug Deliv Lett. 2022;12(1):2-18. doi:10.2174/2210303112666220224110100.
  31. Monti D, Egiziano E, Burgalassi S, Tampucci S, Terreni E, Tivegna S, et al. Influence of a combination of chemical enhancers and iontophoresis on in vitro transungual permeation of nystatin. AAPS PharmSciTech. 2018;19(4):1574-81. doi:10.1208/s12249-018-0977-4.
  32. Souza AM, Ribeiro RC, Pinheiro KK, Pinheiro FI, Oliveira WN, Souza LB, et al. Polishing the therapy of onychomycosis induced by Candida spp.: amphotericin B–loaded nail lacquer. Pharmaceutics. 2021;13(6):784. doi:10.3390/pharmaceutics13060784.
  33. Dehari D, Mehata AK, Priya V, Parbat D, Kumar D, Srivastava AK, et al. Luliconazole nail lacquer for the treatment of onychomycosis: formulation, characterization and in vitro and ex vivo evaluation. AAPS PharmSciTech. 2022;23(6):1-17. doi:10.1208/s12249-022-02324-7.
  34. Tampucci S, Terreni E, Zucchetti E, Burgalassi S, Chetoni P, Monti D. Formulations based on natural ingredients for the treatment of nail diseases. Curr Pharm Des. 2020;26(5):556-65. doi:10.2174/1381612826666200122150248.
  35. Tiwary AK, Sapra B. High failure rate of transungual drug delivery: need for new strategies. Ther Deliv. 2017;8(5):239-42. doi:10.4155/tde-2016-0090.
  36. Vikas A, Rashmin P, Mrunali P, Chavan RB, Kaushik T. Mechanistic insights of formulation approaches for the treatment of nail infection: conventional and novel drug delivery approaches. AAPS PharmSciTech. 2020;21(2):1-12. doi:10.1208/s12249-019-1591-9.
  37. Mididoddi PK, Repka MA. Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur J Pharm Biopharm. 2007;66(1):95-105. doi:10.1016/j.ejpb.2006.08.013.
  38. Gao F, Zhang Z, Bu H, Huang Y, Gao Z, Shen J, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Control Release. 2011;149:168-74. doi:10.1016/j.jconrel.2010.10.013.
  39. Chellapa P, Mohamed AT, Keleb EI, Elmahgoubi A, Eid AM, Issa YS, et al. Nanoemulsion and nanoemulgel as a topical formulation. IOSR J Pharm. 2015;5:43-7.
  40. Gannu R, Palem CR, Yamsani VV, Yamsani SK, Yamsani MR. Enhanced bioavailability of lacidipine via microemulsion-based transdermal gels: formulation optimization, ex vivo, and in vivo characterization. Int J Pharm. 2010;388:231-41. doi:10.1016/j.ijpharm.2009.12.050.
  41. Aithal GC, Narayan R, Nayak UY. Nanoemulgel: a promising phase in drug delivery. Curr Pharm Des. 2020;26:279-91. doi:10.2174/1381612826666191226100241.
  42. Sengupta P, Chatterjee B. Potential and future scope of nanoemulgel formulation for topical delivery of lipophilic drugs. Int J Pharm. 2017;526:353-65. doi:10.1016/j.ijpharm.2017.04.068.
  43. Formariz TP, Sarmento VHV, Silva-Junior AA, Scarpa MV, Santilli CV, Oliveira AG. Doxorubicin biocompatible O/W microemulsion stabilized by mixed surfactant containing soya phosphatidylcholine. Colloids Surf B Biointerfaces. 2006;51:54-61. doi:10.1016/j.colsurfb.2006.05.005.
  44. Shirwaikar AA, Thomas T, Shirwaikar A, Lobo R, Prabhu KS. Treatment of onychomycosis: an update. Indian J Pharm Sci. 2008;70(6):710. doi:10.4103/0250-474X.49088.
  45. Souza AMS, Ribeiro RCA, Pinheiro GKL, Pinheiro FI, Oliveira WN, Souza LBF, et al. Polishing the therapy of onychomycosis induced by Candida spp.: amphotericin B–loaded nail lacquer. Pharmaceutics. 2021;13(6):784. doi:10.3390/pharmaceutics13060784.
  46. Barot BS, Parejiya PB, Patel HK, Mehta DM, Shelat PK. Microemulsion-based antifungal gel delivery to nail for the treatment of onychomycosis: formulation, optimization, and efficacy studies. Drug Deliv Transl Res. 2012;2(6):463-76. doi:10.1007/s13346-012-0109-8.
  47. Agrawal V, Patel R, Patel M, Thanki K, Mishra S. Design and evaluation of microemulsion-based efinaconazole formulations for targeted treatment of onychomycosis through transungual route: ex vivo and nail clipping studies. Colloids Surf B Biointerfaces. 2021;201:111652. doi:10.1016/j.colsurfb.2021.111652.
  48. Mahtab A, Anwar M, Mallick N, Naz Z, Jain GK, Ahmad FJ. Transungual delivery of ketoconazole nanoemulgel for the effective management of onychomycosis. AAPS PharmSciTech. 2016;17(6):1477-90. doi:10.1208/s12249-016-0488-0.
  49. Šveikauskait? I, Briedis V. Effect of film-forming polymers on release of naftifine hydrochloride from nail lacquers. Int J Polym Sci. 2017;1-7. doi:10.1155/2017/1476270.
  50. Thatai P, Sapra B. Terbinafine hydrochloride nail lacquer for the management of onychomycosis: formulation, characterization, and in vitro evaluation. Ther Deliv. 2018;9(2):99-119. doi:10.4155/tde-2017-0069.
  51. Kushwaha AS, Sharma P, Shivakumar HN, Rappleye C, Zukiwski A, Proniuk S, et al. Trans-ungual delivery of AR-12, a novel antifungal drug. AAPS PharmSciTech. 2017;18(7):2702-5. doi:10.1208/s12249-017-0752-y.

Reference

  1. Hussan D, Choudhary SR, Sharma D, Bhandari V, Singh M. Transungual drug delivery: a novel approach with unique features. Indo Am J Pharm Res. 2013;3(6):4460-9. doi:10.1155/2016/1387936.
  2. Firoz S, Sirisha MN, Rajalakshmi R. Transungual drug delivery system: a review. Int J Innov Drug Disc. 2011;1:9-14.
  3. Kumar PT, Narayana RP. Transungual drug delivery: a promising route to treat nail disorders. Int J Pharm Res. 2013;2:22-3.
  4. Verma S, Verma S, Singh R, Ashima A. Transungual drug delivery: a pivotal remedy in onychomycosis. 2016:370-81.
  5. Nikam VK, Kotade KB. Transungual drug delivery system: a review. Pharmacologyonline. 2011;1(1):126-39.
  6. Sahoo CK, Mohanty D. Transungual drug delivery system: a review. Asian J Pharm Res. 2015;5(1):37-44.
  7. Yadav V, Srivastava V, Dwivedi KP, Singh R, Yadav A, Verma NK. Disease of nails (fungal infection), diagnosis, treatment (nail lacquer): a review. World J Pharm Pharm Sci. 2013;11(10):663-94. doi:10.20959/wjpps202210-23344.
  8. Malvade PV, Chavan SR, Bhagat DB, Ghorpade KR. Transungual: the novel drug delivery system. World J Pharm Life Sci. 2020;6(6):265-74.
  9. Basini NP, Dey BK. Nail drug delivery system: a review. J Adv Pharm Educ Res. 2012;2(3):101-9.
  10. Kiran SR, Chandra Shekar B. Ungual drug delivery system of ketoconazole nail lacquer. Int J Appl Pharm. 2010;2(4):17-9.
  11.  Patel RP, Patel NA. Drug delivery across human nail. Int J Curr Pharm Res. 2009;1(1):17.
  12. Badola A, Satish, Baluni S. A review: transungual drug delivery. Asian J Pharm Sci Technol. 2015;5(4):227-33.
  13.  Rajendra VB, Baro A. Transungual drug delivery: an overview. J Appl Pharm Sci. 2012;2(1):203-9.
  14. Mathew F, Bindumol KC. Understanding our natural nail – antifungal agents. Int J Pharm Pharm Sci. 2014;6(2):918-22.
  15. Patil PS, Badgujar SV. Nailing the nail trouble by transungual drug delivery. Eur J Pharm Med Res. 2015;2(2):551-71.
  16. Mathew F, Alias M. Preungual delivery system – a review. Int J Instit Pharm Life Sci. 2014;4(3):44-63.
  17. Lebo DB, Palliyil B. A novel transungual formulation for delivery of ciclopirox olamine. Int J Pharm Med. 2014;3(3):152-64.
  18. Khan AD, Giri A. Transungual drug delivery: a newer approach. World J Pharm Pharm Sci. 2014;3(3):781-94.
  19. Turner R, Weaver S. A novel vehicle for enhanced drug delivery across the human nail. Int J Pharm Compounding. 2016;20(1):71-80.
  20. Gregoriou S, Mpali N, Vrioni G, Hatzidimitriou E, Chryssou S, Rigopoulos D. Epidemiology of onychomycosis in an academic nail unit in South Greece during a three-year period. Skin Appendage Disord. 2019;6(2):102-7. doi:10.1159/000504812.
  21. Singal A, Khanna D. Onychomycosis: diagnosis and management. Indian J Dermatol Venereol Leprol. 2011;77(6):659. doi:10.4103/0378-6323.86475.
  22. Karuna B, Sreekanth N. Nail drug delivery system: a novel approach for drug delivery system. Int J Pharm Res Bio-Sci. 2013;2(2):313-31.
  23. Bhuptani RS, Deshpande KM. Transungual permeation: current insights. Drug Deliv Transl Res. 2015;1(1):1-14. doi:10.1007/s13346-015-0259-6.
  24. Kushwaha A, Murthy NS. Iontophoresis for drug delivery into the nail apparatus: exploring hyponychium as the site of delivery. Drug Dev Ind Pharm. 2016;1(1):1-17. doi:10.3109/03639045.2016.1165690.
  25. Kushwaha A, Murthy RN. Emerging therapies for the treatment of ungual onychomycosis. Drug Dev Ind Pharm. 2015;1(1):1-7. doi:10.3109/03639045.2015.1033426.
  26. Gupta AK, Simpson FC. Routes of drug delivery into the nail apparatus: implications for the efficacy of topical nail solutions in onychomycosis. J Dermatolog Treat. 2015;1(1):1-3. doi:10.3109/09546634.2015.1034081.
  27. Thatai P, Tiwary AK. Progressive development in experimental models of transungual drug delivery of anti-fungal agents. Int J Cosmet Sci. 2016;38:1-12. doi:10.1111/ics.12230.
  28. Calo E, Khutoryanskiy VV. Biomedical applications of hydrogels: a review of patents and commercial products. Eur Polym J. 2015;65:252-67. doi:10.1016/j.eurpolymj.2014.11.024.
  29. Dhamoon RK, Popli H, Gupta M. Novel drug delivery strategies for the treatment of onychomycosis. Pharm Nanotechnol. 2019;7(1):24-38. doi:10.2174/2211738507666190228104031.
  30. Giri Y, Behera A, Mohanty B, Pattnaik G, Habibullah S. Transungual drug delivery system for the topical treatment of onychomycosis: a review. Drug Deliv Lett. 2022;12(1):2-18. doi:10.2174/2210303112666220224110100.
  31. Monti D, Egiziano E, Burgalassi S, Tampucci S, Terreni E, Tivegna S, et al. Influence of a combination of chemical enhancers and iontophoresis on in vitro transungual permeation of nystatin. AAPS PharmSciTech. 2018;19(4):1574-81. doi:10.1208/s12249-018-0977-4.
  32. Souza AM, Ribeiro RC, Pinheiro KK, Pinheiro FI, Oliveira WN, Souza LB, et al. Polishing the therapy of onychomycosis induced by Candida spp.: amphotericin B–loaded nail lacquer. Pharmaceutics. 2021;13(6):784. doi:10.3390/pharmaceutics13060784.
  33. Dehari D, Mehata AK, Priya V, Parbat D, Kumar D, Srivastava AK, et al. Luliconazole nail lacquer for the treatment of onychomycosis: formulation, characterization and in vitro and ex vivo evaluation. AAPS PharmSciTech. 2022;23(6):1-17. doi:10.1208/s12249-022-02324-7.
  34. Tampucci S, Terreni E, Zucchetti E, Burgalassi S, Chetoni P, Monti D. Formulations based on natural ingredients for the treatment of nail diseases. Curr Pharm Des. 2020;26(5):556-65. doi:10.2174/1381612826666200122150248.
  35. Tiwary AK, Sapra B. High failure rate of transungual drug delivery: need for new strategies. Ther Deliv. 2017;8(5):239-42. doi:10.4155/tde-2016-0090.
  36. Vikas A, Rashmin P, Mrunali P, Chavan RB, Kaushik T. Mechanistic insights of formulation approaches for the treatment of nail infection: conventional and novel drug delivery approaches. AAPS PharmSciTech. 2020;21(2):1-12. doi:10.1208/s12249-019-1591-9.
  37. Mididoddi PK, Repka MA. Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur J Pharm Biopharm. 2007;66(1):95-105. doi:10.1016/j.ejpb.2006.08.013.
  38. Gao F, Zhang Z, Bu H, Huang Y, Gao Z, Shen J, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Control Release. 2011;149:168-74. doi:10.1016/j.jconrel.2010.10.013.
  39. Chellapa P, Mohamed AT, Keleb EI, Elmahgoubi A, Eid AM, Issa YS, et al. Nanoemulsion and nanoemulgel as a topical formulation. IOSR J Pharm. 2015;5:43-7.
  40. Gannu R, Palem CR, Yamsani VV, Yamsani SK, Yamsani MR. Enhanced bioavailability of lacidipine via microemulsion-based transdermal gels: formulation optimization, ex vivo, and in vivo characterization. Int J Pharm. 2010;388:231-41. doi:10.1016/j.ijpharm.2009.12.050.
  41. Aithal GC, Narayan R, Nayak UY. Nanoemulgel: a promising phase in drug delivery. Curr Pharm Des. 2020;26:279-91. doi:10.2174/1381612826666191226100241.
  42. Sengupta P, Chatterjee B. Potential and future scope of nanoemulgel formulation for topical delivery of lipophilic drugs. Int J Pharm. 2017;526:353-65. doi:10.1016/j.ijpharm.2017.04.068.
  43. Formariz TP, Sarmento VHV, Silva-Junior AA, Scarpa MV, Santilli CV, Oliveira AG. Doxorubicin biocompatible O/W microemulsion stabilized by mixed surfactant containing soya phosphatidylcholine. Colloids Surf B Biointerfaces. 2006;51:54-61. doi:10.1016/j.colsurfb.2006.05.005.
  44. Shirwaikar AA, Thomas T, Shirwaikar A, Lobo R, Prabhu KS. Treatment of onychomycosis: an update. Indian J Pharm Sci. 2008;70(6):710. doi:10.4103/0250-474X.49088.
  45. Souza AMS, Ribeiro RCA, Pinheiro GKL, Pinheiro FI, Oliveira WN, Souza LBF, et al. Polishing the therapy of onychomycosis induced by Candida spp.: amphotericin B–loaded nail lacquer. Pharmaceutics. 2021;13(6):784. doi:10.3390/pharmaceutics13060784.
  46. Barot BS, Parejiya PB, Patel HK, Mehta DM, Shelat PK. Microemulsion-based antifungal gel delivery to nail for the treatment of onychomycosis: formulation, optimization, and efficacy studies. Drug Deliv Transl Res. 2012;2(6):463-76. doi:10.1007/s13346-012-0109-8.
  47. Agrawal V, Patel R, Patel M, Thanki K, Mishra S. Design and evaluation of microemulsion-based efinaconazole formulations for targeted treatment of onychomycosis through transungual route: ex vivo and nail clipping studies. Colloids Surf B Biointerfaces. 2021;201:111652. doi:10.1016/j.colsurfb.2021.111652.
  48. Mahtab A, Anwar M, Mallick N, Naz Z, Jain GK, Ahmad FJ. Transungual delivery of ketoconazole nanoemulgel for the effective management of onychomycosis. AAPS PharmSciTech. 2016;17(6):1477-90. doi:10.1208/s12249-016-0488-0.
  49. Šveikauskait? I, Briedis V. Effect of film-forming polymers on release of naftifine hydrochloride from nail lacquers. Int J Polym Sci. 2017;1-7. doi:10.1155/2017/1476270.
  50. Thatai P, Sapra B. Terbinafine hydrochloride nail lacquer for the management of onychomycosis: formulation, characterization, and in vitro evaluation. Ther Deliv. 2018;9(2):99-119. doi:10.4155/tde-2017-0069.
  51. Kushwaha AS, Sharma P, Shivakumar HN, Rappleye C, Zukiwski A, Proniuk S, et al. Trans-ungual delivery of AR-12, a novel antifungal drug. AAPS PharmSciTech. 2017;18(7):2702-5. doi:10.1208/s12249-017-0752-y.

Photo
Monika Nijhawan
Corresponding author

Gokaraju Rangaraju College of Pharmacy

Photo
Samyuktha Kypa
Co-author

Gokaraju Rangaraju College of Pharmacy

Photo
Nandini Kongara
Co-author

Gokaraju Rangaraju College of Pharmacy

Photo
Bhavana Pappala
Co-author

Gokaraju Rangaraju College of Pharmacy

Photo
Rajeswari Aleti
Co-author

Gokaraju Rangaraju College of Pharmacy

Photo
Sailaja Gunnam
Co-author

Gokaraju Rangaraju College of Pharmacy

Photo
Kabita Banik
Co-author

Gokaraju Rangaraju College of Pharmacy

Monika Nijhawan, Samyuktha Kypa, Nandini Kongara, Bhavana Pappala, Rajeswari Aleti, Sailaja Gunnam, Kabita Banik, A Comprehensive Review on Transungual Drug Delivery: From Nail Anatomy to Treatment of Onychomycosis, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 6, 3481-3494. https://doi.org/10.5281/zenodo.15719402

More related articles
Formulation And Evaluation of Herbal Shampoo for P...
Rohan Morpake , Ketan Uike, Janhavi Bure, Shilpa Jaiswal , Dr. M....
Formulation And Evaluation of Herbal Hair Conditio...
Harishchandre Swapnil , Anap Jyoti , Andhale Shubhangi , Andhale ...
A Systemic Review on Plant Based Anti-Inflammatory...
Prajapati Rahul, Gohil Malvi, Karodiya Snehal, Saiyad Suzannisha,...
Theranostic Nanomedicine for Cancer Diagnosis and Treatment...
Narendra Umale, Akash Malthankar, Nurvi Deshmukh, Sakshi Thakur, Dr. H. Sawarkar, ...
Pharmacological Review On: Ziziphus Mauritiana ...
Khushal Chaudhari, Lilachand Patil, Narendrasing Ranjitsing Girase, Shantvan Salunke, Kanhaiyalal Pa...
Anti- Hypertensive Activity Of Ginger, Cardamom, Garlic...
Misal A. R., Maske Vaishnavi S., Pare Rutuja U., Kharat Anjali S. , ...
Related Articles
Formulation And Evaluation of Effervescent Tablet...
MD Abuzar, Nivedita Chatterjee , ...
Pharmaceutical Preparation And Evaluation Of Herbal Cold Cream ...
Deepali Suryavanshi, Ajit.A.Naik, Anjum.G.Bairagdar, Aditi.R.Patil, Snehal Bongarde , ...
Formulation and Evaluation of Antifungal and Muscle Relaxant Herbal Bath Bomb Co...
Chetan S. Darne, Monika P. Maske, Pawan A. Gore, Jagdish R. Baheti, ...
Formulation And Evaluation of Herbal Shampoo for Promoting Hair Growth and Anti-...
Rohan Morpake , Ketan Uike, Janhavi Bure, Shilpa Jaiswal , Dr. M. D. Kitukale , ...
More related articles
Formulation And Evaluation of Herbal Shampoo for Promoting Hair Growth and Anti-...
Rohan Morpake , Ketan Uike, Janhavi Bure, Shilpa Jaiswal , Dr. M. D. Kitukale , ...
Formulation And Evaluation of Herbal Hair Conditioner by Using Annona Squamosa L...
Harishchandre Swapnil , Anap Jyoti , Andhale Shubhangi , Andhale Tejal , ...
A Systemic Review on Plant Based Anti-Inflammatory Agents...
Prajapati Rahul, Gohil Malvi, Karodiya Snehal, Saiyad Suzannisha, ...
Formulation And Evaluation of Herbal Shampoo for Promoting Hair Growth and Anti-...
Rohan Morpake , Ketan Uike, Janhavi Bure, Shilpa Jaiswal , Dr. M. D. Kitukale , ...
Formulation And Evaluation of Herbal Hair Conditioner by Using Annona Squamosa L...
Harishchandre Swapnil , Anap Jyoti , Andhale Shubhangi , Andhale Tejal , ...
A Systemic Review on Plant Based Anti-Inflammatory Agents...
Prajapati Rahul, Gohil Malvi, Karodiya Snehal, Saiyad Suzannisha, ...